Drug Profile
gMSC 1
Alternative Names: gMSC®1Latest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Two Cells
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Cartilage disorders
Most Recent Events
- 14 Jul 2017 Phase-III clinical trials in Cartilage disorders in Japan (Parenteral) (JapicCTI-173603)
- 05 Jun 2017 Twocells company plans a phase III trial for Cartilage disorders in Japan (JapicCTI-173603)
- 25 Apr 2016 Chugai Pharmaceutical in-licenses Synovium-derived mesenchymal stem cells from Two Cells for development in Japan